A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety, Tolerability and Pharmacokinetics of Single Doses of GSK3923868 Administered Via Dry Powder Inhaler to Healthy Participants of Chinese, Japanese and European Ancestry
Latest Information Update: 25 Nov 2024
Price :
$35 *
At a glance
- Drugs GSK 3923868 (Primary)
- Indications Respiratory tract infections
- Focus Adverse reactions; Pharmacodynamics
- 19 Nov 2024 Status changed from not yet recruiting to completed.
- 03 Sep 2024 New trial record